Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists test transplant to fight leukemia without lifelong drugs

NCT ID NCT04678401

Summary

This early-stage study is testing a new type of stem cell transplant for people with aggressive or hard-to-treat forms of acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if adding special immune cells from a partially matched donor can help the transplant fight the cancer while reducing a dangerous side effect where the donor cells attack the patient's body. Researchers hope this approach can control the disease without requiring patients to take lifelong immunosuppressant drugs.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.